Skip to Content

IGC Pharma Inc IGC

Morningstar Rating
$0.34 −0.01 (1.95%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IGC is trading at a 57% discount.
Price
$0.34
Fair Value
$7.22
Uncertainty
Extreme
1-Star Price
$7.79
5-Star Price
$7.45
Economic Moat
Fvdyf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IGC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.35
Day Range
$0.320.37
52-Week Range
$0.250.49
Bid/Ask
$0.33 / $0.34
Market Cap
$21.81 Mil
Volume/Avg
2 / 281,003

Key Statistics

Price/Earnings (Normalized)
Price/Sales
13.59
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
61

Valuation

Metric
IGC
Price/Earnings (Normalized)
Price/Book Value
1.55
Price/Sales
13.59
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
IGC
Quick Ratio
1.56
Current Ratio
2.90
Interest Coverage
Quick Ratio
IGC

Profitability

Metric
IGC
Return on Assets (Normalized)
−48.63%
Return on Equity (Normalized)
−55.09%
Return on Invested Capital (Normalized)
−53.50%
Return on Assets
IGC
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRVfk$541.7 Bil
VRTX
Vertex Pharmaceuticals IncCkmpc$111.3 Bil
REGN
Regeneron Pharmaceuticals IncXnqtzb$109.0 Bil
MRNA
Moderna IncFxsj$36.8 Bil
ARGX
argenx SE ADRMhyc$24.3 Bil
BNTX
BioNTech SE ADRGsxh$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncRxsxvd$20.0 Bil
BMRN
Biomarin Pharmaceutical IncFdtjntw$17.1 Bil
RPRX
Royalty Pharma PLC Class ATpyxvww$14.0 Bil
INCY
Incyte CorpVlvwy$13.7 Bil

Sponsor Center